Abstract
The market for Asia Pacific orthopedic biomaterials will be primarily driven
by the region' s aging population that requires greater care and maintenance of
their bones and joints. The hyaluronic acid viscosupplementation segment will
be favorably affected by both the aging and physically active demographics, as
well as rising awareness of the treatment' s benefits among physicians and
patients. The market will, however, be limited by price competition and
reimbursement challenges. Some of the countries in this market will experience
reimbursement cuts for HA viscosupplementation treatments, while these
treatments are not covered at all in other countries. The bone graft
substitute (BGS) market will be fueled by increasing surgeon and patient
awareness of the advantages of these materials over autografts. In addition,
the introduction of bone morphogenetic proteins (BMPs) into the South Korean
market will cause a surge in revenues; however, strong cost-consciousness
among Asia Pacific hospitals will continue to hinder the growth of this market.
| 
View Cart
